Identification of lethal microRNAs specific for head and neck cancer

Marlon Lindenbergh-van der Plas1, Sanne R Martens-de Kemp, Michiel de Maaker

  • 1Authors' Affiliations: Departments of Otolaryngology/Head-Neck Surgery, Epidemiology and Biostatistics, and Pathology, VU University Medical Center; Department of Mathematics, VU University; Division of Gene Regulation, The Netherlands Cancer Institute, Amsterdam; and InteRNA Technologies BV, Utrecht, The Netherlands.

Abstract

Insights

Researchers discovered six microRNAs that kill head and neck cancer cells but not normal cells. These microRNAs target the ATM gene, offering a potential new therapy for head and neck squamous cell carcinomas.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Head and neck squamous cell carcinomas (HNSCC) have a poor prognosis, necessitating new therapeutic strategies.
  • MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and have roles in cancer development.
  • Identifying tumor-specific lethal miRNAs could lead to novel anti-cancer treatments.

Purpose of the Study:

  • To identify microRNAs that selectively kill HNSCC cells.
  • To investigate the genes targeted by these tumor-selective lethal miRNAs.
  • To evaluate the therapeutic potential of these miRNAs and their targets in HNSCC.

Main Methods:

  • Functional genetic screening using a retroviral expression library of human miRNAs in HNSCC cell lines and normal keratinocytes.
  • Gene expression profiling to identify downstream targets of candidate miRNAs.
  • 3'-untranslated region (UTR) luciferase reporter assays and functional assays to validate miRNA targets.

Main Results:

  • Six microRNAs were identified that selectively inhibit HNSCC cell proliferation.
  • The ataxia telangiectasia mutated (ATM) gene was identified as a common target for multiple identified miRNAs.
  • Inhibition of ATM mimicked the tumor-specific lethal effect of the miRNAs, and rescue experiments confirmed this finding.

Conclusions:

  • The identified six microRNAs show potential as novel anti-cancer agents for HNSCC.
  • The ataxia telangiectasia mutated (ATM) gene represents a promising therapeutic target for head and neck cancer treatment.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...